The new england journal of medicine n engl j med 353;17 www.nejm.org october 27, 2005 1856 correspondence Benign Breast Disease and Breast Cancer to the editor: The article on the risk of cancer in patients with benign breast disease by Hartmann et al. (July 21 issue) 1 contains some questionable assumptions. "Atypical ductal hyperplasia" and "lobular hyperplasia," shown in Figure 1E and Figure 1F of the article, do not belong in the category of benign breast disease. Experienced pathologists know that the differentiation of the so-called atypical ductal hyperplasia from an intraductal carcinoma of the breast is extremely difficult in most cases and impossible in some. 2 Lobular hyperplasia, shown in Figure 1F , is closely related to lobular carcinoma in situ, recognized for generations as a precursor lesion of breast cancer. 3 Thus, these two types of lesions should be classified as precursors of mammary carcinoma, as demonstrated by a much higher rate of subsequent breast cancer in patients with these lesions than in patients with truly benign disorders. One would have expected an even higher rate of cancer in patients who were apparently not treated, except for excision of the lesion. The issue of lesion classification and risk is even more important if this information is shared with patients, as suggested by Elmore and Gigerenzer, in the accompanying editorial. to the editor: In their editorial, Elmore and Gigerenzer offer insightful comments on the risk of risk communication. They state that risk can be communicated in terms of absolute risks, "which foster insight" and are "clearer." They recommend the use of the number needed to treat as a "clear" form of communication. We agree that decisions usually should be based on absolute risks, but to our knowledge, there is no evidence that absolute risk reduction or its reciprocal number needed to treat is clear or fosters insight. Rather, there is ample evidence that laypersons and professionals misunderstand number needed to treat. [1][2][3] [4] Elmore and Gigerenzer claim that "the use of relative risks suggests greater effects than truly exist, whereas . . . absolute risks . . . prevents this misunderstanding." Both relative risk and absolute risk, however, are arithmetic reformulations of the same numbers and are therefore equally correct. In order to establish that one of them is more misinterpreted than the other would require a gold standard for correct interpretation. To our knowl- the authors reply: Drs. Koss and Fineberg correctly note that atypical ductal hyperplasia and atypical lobular hyperplasia form a morphologic continuum with ductal carcinoma in situ and lobular carcinoma in situ, respectively. The microscopical distinction can be difficult and is based on a number of criteria including severity of cytologic atypia, degree of alteration in architectural cellular relationships, and extent of lesions. Not all these features can be represented in a single high-power view. The epidemiologic results in our study support the accuracy of our pathological assessment. Namely, the relative risk for atypical hyperplasia in our study is 4.2, entirely consistent with other major reports. 1,2 If our atypia group had included significant numbers of cases of ductal carcinoma in situ and lobular carcinoma in situ, we would expect relative risks in the range of 10 or greater. 3 We do not understand the comments by Koss and Fineberg regarding precursor lesions. Many experts in the field consider atypia, especially atypical ductal hyperplasia, to be a precursor lesion to breast cancer. Our data show a slightly increased risk of ipsilateral cancer in women with atypia, compatible with the hypothesis that some atypias represent direct precursors. the editorialists reply: It should be alarming that most physicians and patients do not understand the crucial numbers that medical research provides for them. Collective innumeracy is an impediment to the efficacy of evidence-based medicine and shared decision making. Research on how to frame numbers so that physicians and patients understand them is still scarce.
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Dr. Kristiansen and colleagues ask whether there is evidence that relative risks confuse people more than absolute risks or number needed to treat. In fact, several studies have shown that statements referring to relative risks make benefits appear greater to patients as well as to physicians and policymakers, whereas statements referring to absolute risks or number needed to treat make benefits appear smaller. For example, people's willingness to accept medication or screening is substantially greater when the benefits are framed in terms of relative risks. 1,2 Physicians' treatment decisions can also be affected by the way in which research results are summarized. 3 One notable study even found that health authorities were much more likely to fund a proposal for cardiac interventions and breast-cancer interventions when the benefits were framed in terms of relative risks than they were to fund an identical proposal with benefits that were framed in terms of absolute risks and number needed to treat. 4 Kristiansen et al. cite studies by Sheridan et al., who conclude that discussions of absolute risks and number needed to treat may not foster insight. Yet the apparently discrepant results from Sheridan et al. might be due to the researchers' unusual expression of these numbers. 5 Physicians rarely quantify risks or benefits when talking with patients. Instead, we tend to use qualitative terms that might be ambiguous, such as "You are at increased risk of breast cancer" or "You are at high risk of breast cancer." The way patients interpret such qualitative statements can vary widely, with a corresponding effect on the medical care that we provide. Thus we suggest using numbers along with qualitative terms to minimize ambiguity.
At issue is transparency and clarity in communications with patients. All of the foregoing enforces one conclusion: we need to overhaul our education- 
